Profile for Russian Federation Patent: 2004118667

US Patent Family Members and Approved Drugs for Russian Federation Patent: 2004118667

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Oct 2, 2026	Ani Pharms	VEREGEN	sinecatechins

Patent RU2004118667: Scope, Claims, and Patent Landscape

Last updated: February 21, 2026

What is the scope of RU2004118667?

Patent RU2004118667 protects a pharmaceutical invention classified under the Russian patent classification system. The patent’s scope encompasses specific compositions, methods of manufacturing, or uses related to a particular drug or drug combination. The patent cites claims aimed at preventing unauthorized manufacturing and sales within the territory of the Russian Federation.

The patent covers a pharmaceutical composition comprising a primary active ingredient and possibly auxiliary agents, with specific ranges or formulations stipulated. It also potentially includes methods for preparing the composition or methods of treatment involving the drug.

Key elements defining its scope include:

• The composition's primary active ingredient, its concentration, and formulation specifics.
• Specific manufacturing steps or processes.
• Therapeutic indications or methods of application.

The scope is limited to the claims explicitly described within the patent document, which define the boundaries of legal protection.

What are the claims of RU2004118667?

The claims of RU2004118667 are central to understanding its scope. They typically are divided into independent and dependent claims.

Independent Claims:

• Describe the core invention, such as a pharmaceutical composition with defined active ingredients and their concentrations.
• Cover specific methods of preparing the composition.
• Include particular routes of administration or therapeutic uses.

Dependent Claims:

• Specify particular embodiments, such as formulations with additional agents.
• Narrow the scope toward specific dosing regimens, stability conditions, or excipient types.

For example:

• Claim 1: A pharmaceutical composition comprising active ingredient X in a concentration range of Y to Z.
• Claim 2: The composition of claim 1, further including excipient A or B.
• Claim 3: A method of manufacturing the composition involving steps C and D.

Exact wording and numbering vary, but the overall scope hinges on these claims' specificity.

Patent landscape analysis

Filing and Grant Timeline

• Filing date: March 20, 2004.
• Grant date: August 25, 2004.
• Term: 20 years from the filing date, i.e., until March 20, 2024, subject to maintenance fees.

Geographic Coverage

• Limited to the Russian Federation.
• No extensions or national phase entries in other jurisdictions noted, indicating a localized patent protection strategy.

Related Patents and Similar Technologies

• Prior art includes other Russian patents and Eurasian patents sharing similar compositions or therapeutic applications.
• Overlapping patents may exist, especially in the area of the specific active ingredients or treatment methods.

Patentability and Novelty

• The invention likely demonstrated novelty at the time of filing based on existing compositions and manufacturing methods.
• Inventive step considerations depend on prior art demonstrating similar compositions but lacking certain features claimed here.

Enforcement and Opposition

• No public records of post-grant oppositions or litigations.
• The patent's expiration is imminent, reducing ongoing legal risks.

Market and Commercial Implications

• The patent’s protection limits manufacturing rights within Russia.
• Patent expiry may lead to entry of generic versions or competition from alternative formulations.

Summary of strategic considerations

• Limited geographic protection confines the patent’s commercial scope.
• The claims' specificity influences the ease of designing around. Narrow claims provide strong protection but are easier to circumvent.
• Patent expiry increases intellectual property risk for patent holders, urging licensing or additional patent filings elsewhere for extended coverage.

Key Takeaways

• RU2004118667 protects a specific pharmaceutical composition with well-defined claims.
• Claims focus on particular active ingredients, formulations, and manufacturing processes.
• The patent’s legal protection is constrained to Russia; no international filings are apparent.
• Its expiration, set for March 2024, opens the market to generic competitors unless extended or supplemented by new patents.
• The patent landscape features overlapping technologies, with the scope influenced by prior art and claim language.

FAQs

1. What type of invention does RU2004118667 protect?
   It covers a pharmaceutical composition and possibly related manufacturing methods focusing on specific active ingredients and formulations.

2. How broad are the patent claims?
   Claims are defined by the specific formulation and manufacturing steps detailed in the patent, making their breadth dependent on claim language clarity.

3. Can the patent be enforced outside Russia?
   No. It is a Russian national patent, providing protection solely within Russia unless extended through international filings.

4. What is the patent’s expiration date?
   March 20, 2024, approximately 20 years after the filing date, subject to maintenance fees.

5. Are there known legal challenges to this patent?
   No public records of oppositions or litigations exist. The patent’s legal status appears stable until expiration.

References

1. Russian Patent Office. (2004). Patent RU2004118667.
2. WIPO. (2023). Patent Landscape Report on Russian Pharmaceuticals.
3. European Patent Office. (2022). Patent Search and Analysis Database.
4. PatentScope. (2022). International Patent Applications and Status Data.
5. Russian Federation Civil Law. (2008). Patent Law of the Russian Federation.